SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is surging on overwhelmingly positive Phase 2 S-OLARIS trial results for sonelokimab in axSpA, which demonstrated exceptional efficacy and potential disease-modifying effects, further bolstered by a robust financial outlook. The community is actively discussing the drug's best-in-class potential, its significant market opportunity, and a major institutional buy-in, fueling expectations for a substantial re-evaluation and potential short squeeze ahead of its Investor Day.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx is trending as Gilead Sciences announced its acquisition for $7.8 billion, with the community focusing on the substantial premium and the strategic value of Arcellx's promising CAR T-cell therapy, anito-cel, which has shown strong clinical data for multiple myeloma.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for AXS-05 in Alzheimer's disease agitation, setting an April PDUFA date, alongside robust Q4 earnings and strong commercial growth for its CNS therapies. The community is highly optimistic about AXS-05's market potential and the company's trajectory towards cash flow positivity, further supported by multiple analyst upgrades and pipeline advancements.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's is trending after reporting Q4 earnings with strong revenue and a dividend increase, though an EPS miss has fueled community debate over its "Hungry for MORE" strategy driving market share gains against competitive and macro pressures.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug

Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.read more...

Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more

These are the stocks posting the largest moves in premarket trading...

ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Arcellx, Inc. (NASDAQ: ACLX) to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of...

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion...

Shares of Arcellx Inc (ACLX) surged nearly 80% in pre-market trading on Monday after Gilead Sciences, Inc. (GILD) announced an agreement to acquire Arcellx in a deal worth around $7.8 billion.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/ACLX">ACLX shares</a> will hit an all-time high. Meanwhile, <a href="https://stocktwits.com/symbol/GILD">GILD shares</a> traded 1.2% lower in pre-market trading.<h2 class="st-heading-2">Gilead Sciences To Acquire Arcellx</h2>Under the agreement, Gilead will pay $115 per share in cash plus a $5 contingent value right (CVR) tied to future sales milestones. The offer is a 68% premium to Arcellx’s 30-day average share price as of Feb. 20, 2026.Gilead, which already owns roughly 11.5% of Arcellx, will launch a tender offer for the remaining shares. The deal is expected to close in the second quarter of 2026.The acquisition is projected to boost Gilead’s earnings per share starting in 2028, following potential U.S. Food and&nbsp;Drug&nbsp;Administration (FDA) approval of anito-cel, a treatment for multiple myeloma, a type of blood cancer.Get updates to this developing story on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did ACLX Stock Surge 80% In Pre-Market Today?

Shares of Arcellx Inc (ACLX) surged nearly 80% in pre-market trading on Monday after Gilead Sciences, Inc. (GILD) announced an agreement to acquire Arcellx in a deal worth around $7.8 billion.

Equity

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value...

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Key PointsPerceptive Advisors sold 1,002,282 Arcellx shares in the fourth quarter; the estimated trade size was $79.96 million based on quarterly average pricing...

78,589 Shares in Arcellx, Inc. $ACLX Acquired by Monaco Asset Management SAM

Monaco Asset Management SAM acquired a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm...

Arcellx (ACLX) Expected to Announce Earnings on Thursday

Arcellx (NASDAQ:ACLX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition

Key PointsFirst Turn Management sold 313,733 shares of Arcellx in the fourth quarter...

Tech stocks

Energy

Cash / Bonds

Crypto

What&#39;s your biggest portfolio allocation right now?

Stocktwits

What's your biggest portfolio allocation right now?

Stocktwits Polls

Traders are heavily discussing Gilead Sciences' definitive agreement to acquire Arcellx for $115 per share in cash, a deal valued at $7.8 billion.

The stock experienced a massive pre-market surge, climbing nearly 80% immediately following the acquisition announcement.

The significant acquisition is sparking discussions and speculation about increased merger and acquisition activity across the broader biotech sector.

ACLX
Arcellx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACLX News

ACLXArcellx Inc